Population Pharmacokinetics in Benznidazol-treated adults with Chronic Chagas Disease. Benznidazol Pharmacokinetics and adverse reactions relationship. - Population Pharmacokinetics in Benznidazol-treated adults with Chronic Chagas Disease

CRESIB- International Research Center in Health of Barcelona0 个研究点开始时间: 2011年12月21日最近更新: 2014年6月30日

适应症

试验速览

暂无简介。

•- Adult patients with Chronic Chagas Disease diagnosed by 2 different and positive serological tests.
•- Patients with Chronic Chagas Disease who are going to start treatment with Benznidazol.
•- Any gender.
•- All the participants must agree to participate in the study and must sign the informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Patients yonger than 18.
•- Patients with previous hipersensitivity to Benznidazol.
•- Inmunocompromised patients as AIDS, cancer, chemoterapy, long-term corticoids need, primary inmunodeficiency, or any other.
•- Hepatic dysfunction
•- Renal dysfunction: serum creatinin higher than 3 mg/dl.
•- Pregnancy or lactation.
•- Low adhesion to treatment or check-up.
•- Imposibility of follow-up.
•- Severe adverse reaction to Benznidazol.
•- Any other situation that could be risky for the patient.

发起方

CRESIB- International Research Center in Health of Barcelona